FASENRA®


 
 
 
 
 
 
 
 
 


 

FASENRA® (Benralizumab) is an immunosuppressive drug that is used as an add-on maintenance therapy for patients with severe Eosinophilic Asthma.

FASENRA® is manufactured by AstraZeneca.

Administration and Dosage:

Administration of FASENRA® follows an induction regimen of 3 subcutaneous injections every 4 weeks followed by a maintenance injection, once every 8 weeks.

Common Side Effects:

The more common side effects of FASENRA® include allergic (hypersensitivity) reactions, including anaphylaxis.

More Information:

Please read the full Prescribing Information and Instructions for Use for FASENRA® and discuss any questions you have with your doctor.

Ready to Schedule an Appointment?

Please CLICK HERE to get started.

Indication:

FASENRA® is indicated to treat:

  • Add-on Maintenance for Severe Eosinophilic Asthma